Please assess the completion status of the following clinical trial:

Trial Title: Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.~* A male or female between, and including, 12 and 23 months of age at the time of the vaccination.~* Written informed consent obtained from the parent or guardian of the subject.~* Free of obvious health problems as established by medical history and clinical examination before entering into the study.~* Previously completed routine childhood vaccinations to the best of parents' or legal guardians' knowledge.~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the vaccine dose.~* Planned administration/ administration of a vaccine not foreseen by the study protocol within one month before and 42 days after the first dose of vaccine(s).~* Previous vaccination with meningococcal vaccine of serogroup A, C W and/or Y.~* History of meningococcal disease.~* Previous vaccination against measles, mumps, rubella, and/or varicella.~* History of measles, mumps, rubella and/or varicella.~* Known exposure to measles, mumps, rubella, varicella or zoster within 30 days prior to vaccination.~* Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary), including human immunodeficiency virus (HIV) infection, based on medical history and physical examination.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, including neomycin.~* Major congenital defects or serious chronic illness.~* Acute disease at the time of enrolment.~* Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 23 Months
- Healthy Volunteers: t

Study Arms:
- Nimenrix + Priorix-Tetra Group (Type: EXPERIMENTAL): Subjects received 1 dose of Nimenrix vaccine and 1 dose of Priorix-Tetra vaccine on Day 0 and a second dose of Priorix-Tetra vaccine on Day 84.
- Nimenrix Group (Type: EXPERIMENTAL): Subjects received 1 dose of Nimenrix vaccine on Day 0 followed by 2 doses of Priorix-Tetra vaccine, respectively 42 and 84 days later.
- Priorix-Tetra Group (Type: ACTIVE_COMPARATOR): Subjects received 1 dose of Priorix-Tetra vaccine on Day 0, 1 dose of Meningitec vaccine on Day 42 and a second dose of Priorix-Tetra vaccine on Day 84.
- Meningitec Group (Type: ACTIVE_COMPARATOR): Subjects received 1 dose of Meningitec vaccine on Day 0 followed by 2 doses of Priorix-Tetra vaccine, respectively 42 and 84 days later.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete